Literature DB >> 29552158

Epidermal growth factor receptor expression affects proliferation and apoptosis in non-small cell lung cancer cells via the extracellular signal-regulated kinase/microRNA 200a signaling pathway.

Ping Zhou1, Jian Hu1, Xiaoqin Wang1, Jingyuan Wang1, Yong Zhang2, Cong Wang1.   

Abstract

The present study assessed the function of epidermal growth factor receptor (EGFR) and its molecular targets in non-small cell lung cancer. The results of the present study demonstrated that EGFR protein and mRNA expression in the normal adjacent tissue specimens was decreased compared with that in the lung cancer tissue samples. Compared with the BEAS-2B normal bronchial epithelial cells, EGFR and phosphorylated (p)-extracellular signal-regulated kinase (ERK) protein expression in the SW-900 and A549 lung cancer cells was increased and microRNA (miR)200a expression in the SW-900 and A549 cells was inhibited compared with the BEAS-2B cells. Downregulating miR200a expression significantly suppressed proliferation and promoted apoptosis and caspase (CASP)3 and CASP9 function in the A549 cells and significantly inhibited EGFR and p-ERK protein expression in the A549 cells, compared with the BEAS-2B cells. The results of the present study indicated that downregulating miR200a significantly suppressed proliferation and promoted apoptosis in A549 cells via the regulation of the EGFR and ERK 1/2 signaling pathways.

Entities:  

Keywords:  epidermal growth factor receptor; extracellular signal-regulated kinase 1/2; microRNA 200a; non-small cell lung cancer

Year:  2018        PMID: 29552158      PMCID: PMC5840500          DOI: 10.3892/ol.2018.7961

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  27 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  The dynamic subcellular localization of ERK: mechanisms of translocation and role in various organelles.

Authors:  Ehud Wainstein; Rony Seger
Journal:  Curr Opin Cell Biol       Date:  2016-01-29       Impact factor: 8.382

3.  Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC).

Authors:  Daniel J Allendorf; Rodolfo E Bordoni; Stefan C Grant; Mansoor N Saleh; Vishnu B Reddy; Mary L Jerome; Pamela M Dixon; Deborah K Miley; Karan P Singh; Francisco Robert
Journal:  Cancer Chemother Pharmacol       Date:  2015-09-22       Impact factor: 3.333

4.  Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.

Authors:  Na Li; Huanhuan Li; Fan Su; Jing Li; Xiaoping Ma; Ping Gong
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

5.  Polymorphisms in epidermal growth factor receptor (EGFR) and AKT1 as possible predictors of clinical outcome in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.

Authors:  Xiaoqing Zhang; Junwei Fan; Yuping Li; Shengtao Lin; Ping Shu; Jian Ni; Shengying Qin; Zhemin Zhang
Journal:  Tumour Biol       Date:  2015-08-14

6.  EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB.

Authors:  Kailong Lin; Jianan Cheng; Tao Yang; Yongsheng Li; Bo Zhu
Journal:  Biochem Biophys Res Commun       Date:  2015-05-18       Impact factor: 3.322

7.  Preliminary Evidence on the Diagnostic and Molecular Role of Circulating Soluble EGFR in Non-Small Cell Lung Cancer.

Authors:  Filippo Lococo; Massimiliano Paci; Cristian Rapicetta; Teresa Rossi; Valentina Sancisi; Luca Braglia; Silvio Cavuto; Alessandra Bisagni; Italia Bongarzone; Douglas M Noonan; Adriana Albini; Sally Maramotti
Journal:  Int J Mol Sci       Date:  2015-08-19       Impact factor: 5.923

8.  MicroRNA-545 suppresses cell proliferation by targeting cyclin D1 and CDK4 in lung cancer cells.

Authors:  Bowen Du; Zhe Wang; Xin Zhang; Shipeng Feng; Guoxin Wang; Jianxing He; Biliang Zhang
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

9.  CBP501 inhibits EGF-dependent cell migration, invasion and epithelial-to-mesenchymal transition of non-small cell lung cancer cells by blocking KRas to calmodulin binding.

Authors:  Naoya Saito; Naoki Mine; Donald W Kufe; Daniel D Von Hoff; Takumi Kawabe
Journal:  Oncotarget       Date:  2017-06-22

10.  Increased expression of the Th17-IL-6R/pSTAT3/BATF/RorγT-axis in the tumoural region of adenocarcinoma as compared to squamous cell carcinoma of the lung.

Authors:  Ljubov Balabko; Katerina Andreev; Nadine Burmann; Melanie Schubert; Martina Mathews; Denis I Trufa; Sarah Reppert; Tilmann Rau; Martin Schicht; Horia Sirbu; Arndt Hartmann; Susetta Finotto
Journal:  Sci Rep       Date:  2014-12-10       Impact factor: 4.379

View more
  2 in total

1.  Novel 2-(5-Aryl-4,5-Dihydropyrazol-1-yl)thiazol-4-One as EGFR Inhibitors: Synthesis, Biological Assessment and Molecular Docking Insights.

Authors:  Tarfah Al-Warhi; Ahmed M El Kerdawy; Mohamed A Said; Amgad Albohy; Zainab M Elsayed; Nada Aljaeed; Eslam B Elkaeed; Wagdy M Eldehna; Hatem A Abdel-Aziz; Miral A Abdelmoaz
Journal:  Drug Des Devel Ther       Date:  2022-05-16       Impact factor: 4.319

2.  MicroRNA-374b inhibits the tumor growth and promotes apoptosis in non-small cell lung cancer tissue through the p38/ERK signaling pathway by targeting JAM-2.

Authors:  Yujun Wang; Lijuan Yu; Tao Wang
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.